Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This is a multicenter Phase 2, multiple dose, dose escalation study to evaluate the safety,
pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SPR001 in adult patients with
classic congenital adrenal hyperplasia (CAH).